Lifecore Biomedical has entered into a new development services agreement with Indomo, a clinical‑stage company focused on at‑home acne treatments. Under the deal, Lifecore will manufacture engineering and clinical batches of Indomo’s corticosteroid drug candidate, DT‑001, for Phase 2 studies scheduled for 2026. The partnership builds on a prior collaboration that included formulation and process optimization and expands Lifecore’s CDMO portfolio beyond its traditional ophthalmic and orthopedic focus into the rapidly growing autoinjector market.
"This work with Indomo highlights the success of our continued efforts to expand beyond our traditional focus in ophthalmic therapies, while also enhancing our leadership in rapidly growing autoinjector technologies," said Paul Josephs, president and chief executive officer of Lifecore. The agreement positions the company to capture new revenue streams and strengthen its competitive moat in the sterile injectable space.
Lifecore’s recent financial results show a mixed picture: revenue growth was driven by hyaluronic acid manufacturing demand, while CDMO revenue declined as prior projects completed. The new Indomo agreement adds a diversified revenue source and mitigates concentration risk in the CDMO segment, supporting the company’s broader growth strategy.
Acne affects 50 million Americans annually, yet only about 1 million receive corticosteroid injections. Indomo’s ClearPen intradermal self‑injection device, paired with DT‑001, targets this large unmet need. The partnership gives Lifecore exposure to a sizable market and aligns with its focus on device‑enabled therapeutics.
"Lifecore's expanding leadership in injectable therapeutics and their commitment to speed and high-quality execution position them as a key partner in advancing our therapeutic pipeline. We are excited to deepen this collaboration as we move into the next phase of development," said Rick Bente, chief executive officer of Indomo.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.